Agenus Inc (AGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$6.86-7.67%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Achieve positive net income: 2026-Q2 net margin -1.6% vs 0% target.
Agenus aims to make a profit soon. Net income rose to $39.2M in Q1 2026. The company improved operating income to $15.1M in Q1 2026. New cancer drug data supports future sales growth.
Revenue is falling slightly and is behind targets. The company faces management changes and legal risks. Recent capital sales may hurt shareholder value.
The market expects about 4% revenue growth. Our fair value is near $18, showing the stock is cheap versus peers. We see risk in revenue and management execution.
Breaks if: New major management departures or legal rulings against company
Breaks if: net income falls below $0 in any quarter after 2026-Q1
Breaks if: operating income falls below $14.4M in any quarter after 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. AGEN is currently loss-making and operates in a volatile management environment, but its recent financial performance has been strong, indicating potential for future growth.
The current valuation suggests that AGEN is considered cheap compared to its peers. The market appears to have a low expectations gap, indicating that it may not be pricing in significant future growth.
Management is focused on advancing clinical development and regulatory approval for its key products, which could drive future performance. However, there is an elevated risk of missing earnings expectations in the near term due to the company's erratic earnings history.
The long-term thesis hinges on AGEN's ability to successfully execute its clinical development plans and manage its capital allocation effectively. Additionally, broader sector performance and economic indicators, such as job reports, will significantly impact investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company extended a loan's maturity. This supports its balance sheet. Analysts reworked pipeline and financing assumptions. This threatens the company's capital allocation outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $33.7M in any quarter after 2026-Q1
Over the next 1 to 3 years, AGEN's trajectory will depend on its management execution and external market conditions. Not investment advice.